Patient no. | CD3−CD56+ | CD3+CD56+ | CD3+CD4+ | CD3+CD8+ | NKG2D+ in CD3−CD56+ | CD16+ in CD3−CD56+ | CXCR3+ in CD3−CD56+ | CXCR4+ in CD3−CD56+ | CX3CR1+ in CD3−CD56+ | NK activity EC50a |
---|---|---|---|---|---|---|---|---|---|---|
1 | 30.18 | 62.53 | NE | NE | NE | NE | NE | NE | NE | 2.61 |
2 | 98.41 | 0.93 | 0.40 | 0.24 | 98.91 | 23.01 | 28.33 | 49.79 | 36.79 | 1.31 |
3 | 81.78 | 16.28 | 17.15 | 0.96 | 96.70 | 20.84 | 48.80 | 21.98 | 28.33 | 1.31 |
4 | 98.75 | 0.91 | 0.55 | 0.13 | 96.28 | 29.47 | 36.67 | 29.78 | 28.37 | 1.61 |
5 | 72.84 | 26.50 | 25.49 | 1.87 | 99.59 | 68.39 | 44.82 | 20.32 | 39.51 | 0.63 |
6 | 95.67 | 3.93 | 3.12 | 0.30 | 99.36 | 60.70 | 56.62 | 23.31 | 42.07 | 0.62 |
7 | 86.25 | 13.27 | 3.87 | 0.24 | 95.20 | 50.29 | 29.04 | 31.34 | 26.79 | 1.39 |
8 | 96.60 | 2.27 | 2.25 | 0.07 | 98.54 | 60.46 | 42.90 | 62.89 | 50.40 | 1.24 |
9 | 84.91 | 14.91 | 10.31 | 2.64 | 98.17 | 72.33 | 41.80 | 37.88 | 62.01 | 0.98 |
10 | 65.94 | 38.83 | 33.61 | 0.23 | 98.67 | 62.79 | 44.04 | 42.40 | 51.40 | 1.88 |
11 | 98.49 | 1.39 | 0.45 | 0.11 | 99.45 | 69.23 | 49.69 | 69.29 | 44.33 | 1.76 |
12 | 78.52 | 21.40 | 11.43 | 0.30 | 97.88 | 73.50 | 61.05 | 37.54 | 70.20 | 1.99 |
13 | 97.23 | 2.57 | 2.60 | 0.11 | 99.00 | 32.88 | 57.66 | 49.55 | 54.89 | 0.59 |
14 | 99.45 | 0.44 | 0.28 | 0.09 | 97.82 | 63.59 | 46.12 | 43.73 | 43.15 | 0.39 |
Median (all enrolled patients) | 90.96 | 8.60 | 3.12 | 0.24 | 98.54 | 60.70 | 44.82 | 37.88 | 43.15 | 1.31 |
Median (ITT population) | 90.96 | 8.60 | 3.50 | 0.24 | 98.36 | 61.75 | 45.47 | 37.71 | 43.74 | 1.28 |